Tegmine Therapeutics is a San Francisco-based biotechnology firm.
Tegmine Therapeutics is private, seed-stage biotech that develops antibody-based therapeutics targeting proteins and their disease-related glycan modifications.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Apr 6, 2022 | Corporate Round | — | 1 | Alloy Therapeutics | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Alloy Therapeutics | Yes | Corporate Round |